ReviewAnnals of gastroenterology
The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management.
Review in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Diagnostic performance of hepatitis C virus core antigen testing for detecting hepatitis C in people living with hepatitis B: a systematic review and meta-analysis.Infectious diseases of poverty · 2024Pooled it
- Prevalence of hepatitis B and C virus infections among visceral leishmaniasis patients: a systematic review and meta-analysis.Frontiers in microbiology · 2024Pooled it
- A Unified Histopathological Framework of Liver Fibrogenesis in Chronic Viral Hepatitis B, C and Coinfection.Diseases (Basel, Switzerland) · 2026Article
- Impact of a pharmacist-led hepatitis C clinic on hepatitis A and B vaccination rates and treatment outcomes: A retrospective cohort study.Journal of managed care & specialty pharmacy · 2026Article
- 2025 KASL clinical practice guidelines for management of hepatitis C.Clinical and molecular hepatology · 2026Article
- Prediction of Treatment Response in Hepatitis B and Hepatitis C Coinfected Patients Using a Leakage-Proof, Internally Validated Logistic Regression Pipeline.Advances in virology · 2026Article
- A self-heating, multi-channel slider cassette for innovative point-of-care molecular diagnostics from whole blood samples.Biosensors & bioelectronics · 2025Article
- Disease burden of chronic hepatitis B and C patients in South Korea: a population-based 16-year cohort study.BMC infectious diseases · 2025Article
- Demographic and Clinical Characteristics of Patients With Hepatitis C and Hepatitis B Co-Infection, Georgia, 2017-2023.Journal of viral hepatitis · 2025Article
- Chronic viral hepatitis B: evaluation of the care of patients monitored at the SMIT in Tivaouane, Sénégal.IJID regions · 2025Article
- Immunological and Virological Responses in Patients with Monoinfection and Coinfection with Hepatitis B and C Viruses in the Brazilian Amazon.Tropical medicine and infectious disease · 2025Article
- The Management of Chronic Hepatitis B: 2025 Guidelines Update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada.Canadian liver journal · 2025Article
- Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality.Journal of viral hepatitis · 2025Article
- HCV and HBV genotypes: vital in the progression of HCV/ HBV co-infection.BMC gastroenterology · 2025Article
- MicroRNA-122 protects against interferon-α-induced hepatic inflammatory response via the Janus kinase-signal transducer and activator of transcription pathway.Endocrine journal · 2025Article
- Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study.PloS one · 2025Article
- Sero-prevalence of Hepatitis B and C at a Primary Health Care Facility in Ghana.African health sciences · 2024Article
- One-step, rapid, nanoparticle-based biosensor platform for the simultaneous identification of hepatitis B virus and hepatitis C virus in clinical applications.BMC microbiology · 2024Article
- Seropositivity and coinfection of hepatitis B and hepatitis C viruses in Central India: A hospital-based study.Journal of family medicine and primary care · 2024Article
- Seroprevalence of hepatitis B and hepatitis C virus among clinically suspected cases of viral hepatitis visiting Guhalla Primary Hospital, Northwest Ethiopia.Scientific reports · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoinfection with either hepatitis B (HBV) or C virus (HCV) represents one of the major causes of chronic liver disease globally. However, in endemic areas a substantial number of patients are infected with both viruses mainly as a result of the common routes of transmission. Numerous studies have demonstrated that dually infected patients carry a greater risk of advanced liver disease, cirrhosis and hepatocellular carcinoma compared with monoinfected patients. The choice of treatment is based on the virological profile of each patient taking into account the dominant virus pattern. In predominant HCV, standard combination treatment with pegylated interferon and ribavirin has proven equally effective in HBV/HCV-coinfected patients as well as in HCV-monoinfected patients. Strikingly, approximately 60% of patients with inactive HBV infection before HCV treatment may present HBV reactivation while others experience hepatitis B surface antigen seroconversion after clearing HCV, demonstrating the complexity of the interaction between the two viruses during the follow up. The therapeutic strategies for the predominant HBV dually infected patients are more vague, although high genetic barrier nucleos(t)ide analogues play an indisputable role. Finally, the recently approved combination treatments for chronic hepatitis C containing direct-acting antivirals may definitely change the treatment protocols in the future although there is no experience with these drugs in dually infected patients until today.
Indexed as
Identifiers
25830779PMC4367211W1658714586What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.